Larotrectinib May Provide Durable Efficacy Across Many Tumor Types - Cancer Network

Cancer Network

Larotrectinib May Provide Durable Efficacy Across Many Tumor Types Cancer Network CHICAGO—Larotrectinib, a selective inhibitor of tropomyosin receptor kinase (TRK) fusion proteins, may provide consistent and durable antitumor activity in TRK fusion cancers, across a wide range of ages and tumor types. In addition, it is well ... and more »

from Health - Google News http://ift.tt/2ro5MjL